BeyondSpring Inc

From Verify.Wiki
Jump to: navigation, search
BeyondSpring Inc
Type Public
Industry Pharmaceuticals
Founded 2013
Headquarters New York, NY, United States
Key people Lan Huang (Co-Founder, CEO), Richard A. Brand (CFO), Ramon W. Mohanlal (Chief Medical Officer), Gordon L. Schooley (Chief Regulatory Officer) [1]
Number of employees 20 [2]

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. It focuses on the development of innovative immuno-oncology cancer therapies. Its products in pipeline includes Plinabulin, an immuno-oncology agent in Phase 3 clinical trial for the reduction of Docetaxel-induced Neutropenia and another Phase 3 clinical trial as an anticancer agent in combination with Docetaxel in advanced non-small cell lung cancer. [3]


Plinabulin is an anti-cancer agent with a unique mechanism of action. It is a multi-target agent that has been shown to exhibit anti-tumor activity through anti-angiogenesis, obliteration of existing tumor vasculature and induction of tumor cell apoptosis via the JNK pathway. [4]
Plinabulin has the potential to fill an unmet medical need by improving outcomes as a second line and third line treatment for patients with advanced non-small cell lung cancer (NSCLC) and preventing neutropenia induced by docetaxel. [5]
As a tubulin depolymerizing agent, Plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment:

  1. Immune enhancing effects via dendritic cell maturation
  2. Tumor cell apoptosis via activation of RAS-JNK pathway
  3. Vascular disruptive effects

Given Plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications:

  • Immuno-oncology, with immune checkpoint inhibitors in NSCLC
  • CNS malignancies including glioblastoma (GBM)
  • KRAS positive mutant cancers



Top 5 Recent Tweets

March 17, 2018ledgerzetteZacks: Analysts Set $56.00 Target Price for Beyondspring Inc $BYSI
March 17, 2018TranscriptDailyBeyondspring Inc $BYSI Given $56.00 Average Price Target by Analysts
March 15, 2018ForTradersBeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018
March 14, 2018dispatchtribuneZacks: Beyondspring Inc $BYSI Receives Consensus Recommendation of “Strong Buy” from Analysts

Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines


Verification history